Fig. 1
From: A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD
Patient flow through the study
Advertisement
Fig. 1 | Respiratory Research
Advertisement
From: A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD
Patient flow through the study
